Novel transcatheter heart valve may be effective for management of high-risk aortic regurgitation
1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who underwent Trilogy TAVI had passed at the 1-year follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Surgery remains the primary intervention for native aortic regurgitation, but high-risk patients lack optimal alternatives. Traditional transcatheter heart valves
Source: 2minutemedicine.com
